Sponsored Content by nRichDX


See The Next Revolution in Liquid Biopsy Sample Prep. More cfDNA, cfRNA, and CTCs. Visit nRichDX in Booth 3721

2 minutes

The content below is part of a paid sponsorship and is not an endorsement by the American Association for Cancer Research® (AACR) nor does it reflect the views or opinions of the AACR.

nRichDX®, best known for the development of its Revolution Sample Prep System™, will be introducing four new products, presenting new data in three posters with collaborators: Agena, Agilent, and OraSure’s Novosanis Division, and exhibiting in booth #3721, just inside the main registration entrance at the American Association for Cancer Research® (AACR) Annual Meeting 2024. Held April 5-10 at the San Diego Convention Center, the conference is dedicated to exploring and recognizing the latest discoveries in cancer research. Exhibits open at 1 PM on Sunday April 7 and close at 12:30 PM on Wednesday April 10.

Meeting attendees considering liquid biopsy assays and the extraction of cfDNA, cfRNA, circulating cell-free total nucleic acid (cfTNA), or the enrichment of circulating tumor cells (CTCs) are encouraged to schedule a meeting or visit the nRichDX booth to see the latest liquid biopsy sample prep solutions and learn more about how extracting higher yields of liquid biopsy analytes can increase assay performance through better sensitivity and earlier detection of targeted oncology markers.

nRichDX is introducing two new instruments at the annual meeting: The Revolution Pro™, a new high throughput automated instrument and the Revolution Plus™, a new semi-manual instrument. nRichDX is also introducing two new nRicher Cartridges, which are easier to use and feature an upgraded input sample capacity. The new nRicher Cartridges have the broadest sample input volume range of any commercially available kit – from as little as 1 mL up to 100 mL in a single extraction, eliminating yield-lowering sample or eluate pooling and sample transfer steps required by other sample prep methods – especially at sample volumes above 4 mL.

The company is also co-presenting three posters at the meeting featuring the Revolution Sample Prep System for liquid biopsy applications:

  • April 8 from 9-12:30 p.m.: Enhancing urine-based cfDNA detection for prostate cancer diagnosis through increased urine input volume, presented in collaboration with Agilent Technologies
  • April 9 from 9-12:30 p.m.: Urine as a non-invasive proxy for plasma in prostate cancer-related liquid biopsy applications, presented in collaboration with OraSure Technologies’ Novosanis Division
  • April 9 from 9-12:30 p.m.: Achieving sensitivity of 0.1% variant allele frequency (VAF) in plasma and urine with the nRichDX revolution sample prep system evaluated on the MassARRAY system, presented in collaboration with Agena Bioscience

To meet with nRichDX people at the annual meeting or schedule an in-booth demo, attendees are encouraged to visit the nRichDX meeting website and schedule an appointment. If you work, or are interested, in liquid biopsy make a point of visiting nRichDX, booth #3721 at the American Association for Cancer Research® (AACR) Annual Meeting 2024.